[G23-25] Loncastuximab tesirine (DLBCL and HGBL) – Addendum to Commission A23-45
Last updated 01.12.2023
Project no.:
G23-25
Commission:
Commission awarded on 26.09.2023 by the Federal Joint Committee (GBA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Health Economics
Topic:
Cancer
Note:
If, in the course of the discussions on a commission of the GBA, a need for further revision arises, IQWiG submits an addendum. The GBA decides on the number of patients in the SHI target population.
The current version 1.1 of the addendum replaces version 1.0 published on 2023-11-17.
DOI:
https://dx.doi.org/10.60584/G23-25_V1.1
| Project no. | Title | Status |
|---|---|---|
| A23-45 | Loncastuximab tesirine (DLBCL and HGBL) - Benefit assessment according to § 35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2023-11-16 A G-BA decision was published.